Tags

Type your tag names separated by a space and hit enter

Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts.
Int J Gynecol Cancer. 2009 Jul; 19(5):934-42.IJ

Abstract

BACKGROUND

New end points are needed in future human papillomavirus (HPV) vaccine efficacy studies that accurately predict disease progression.

OBJECTIVES

Potential intermediate end points were analyzed in the combined New Independent States of the Former Soviet Union (NIS) and the Latin American Screening (LAMS) study cohorts.

STUDY DESIGN AND METHODS

Data files of 2 international screening trials, the NIS (n = 3187) and the LAMS (n = 12,114) study cohorts, were combined, and a subcohort of 1865 (n = 854 and n = 1011 for the NIS and the LAMS, respectively) women prospectively followed up for 19.7 (median, 22.2) months was analyzed for different intermediate end-point markers of disease progression to squamous intraepithelial lesion (SIL), cervical intraepithelial neoplasia grade 1 and higher (CIN1+), and CIN grade 2 and higher (CIN2+) as terminal events.

RESULTS

: Altogether, 131 (7.0%), 90 (4.8%), and 39 (2.1%) cases progressed to SIL, CIN1+, and CIN2+, respectively, progression times being equal in the NIS (11.9, 16.8, and 19.6 months) and LAMS (13.6, 14.1, and 15.4 months) cohorts (P = 0.931, P = 0.335, and P = 0.535). The 2 most powerful end-point markers of disease progression to CIN2+ were high-grade squamous intraepithelial lesions based on Papanicolaou test results at 6-month (odds ratio [OR] = 47.1; 95% confidence interval [CI], 17.3-128.7) and 12-month (OR = 21.5; 95% CI, 5.1-90.8) follow-up visits, with longitudinal positive and negative predictive values of 42.1% and 98.0% (6 months) and 33.3% and 97.7% (12 months). Of the virological end points, more than 6 months of persistent high-risk HPV (HR-HPV) was the most powerful predictor of progression to CIN1+ (OR = 18.6; 95% CI, 2.5-136.5), with longitudinal positive and negative predictive values of 10.3% and 99.4%, respectively. No additional benefit was obtained using more than 12 months of persistent HR-HPV end point.

CONCLUSIONS

High-grade squamous intraepithelial lesion based on a Papanicolaou test results at 6- or 12-month follow-up visits was the most powerful end point, either considering cytological end points alone or in comparison to any of the virological end points. Of the virological end points, more than 6-month HR-HPV persistence criteria give the most powerful estimate of a progressive disease.

Authors+Show Affiliations

Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland. kari.syrjanen@tyks.fiNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19574788

Citation

Syrjänen, Kari, et al. "Persistent High-risk Human Papillomavirus Infections and Other End-point Markers of Progressive Cervical Disease Among Women Prospectively Followed Up in the New Independent States of the Former Soviet Union and the Latin American Screening Study Cohorts." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, vol. 19, no. 5, 2009, pp. 934-42.
Syrjänen K, Shabalova I, Naud P, et al. Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts. Int J Gynecol Cancer. 2009;19(5):934-42.
Syrjänen, K., Shabalova, I., Naud, P., Kozachenko, V., Derchain, S., Zakharchenko, S., Roteli-Martins, C., Nerovjna, R., Longatto-Filho, A., Kljukina, L., Tatti, S., Branovskaja, M., Hammes, L. S., Branca, M., Grunjberga, V., Erzen, M., Sarian, L. O., Juschenko, A., Costa, S., ... Syrjänen, S. (2009). Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society, 19(5), 934-42. https://doi.org/10.1111/IGC.0b013e3181a834fe
Syrjänen K, et al. Persistent High-risk Human Papillomavirus Infections and Other End-point Markers of Progressive Cervical Disease Among Women Prospectively Followed Up in the New Independent States of the Former Soviet Union and the Latin American Screening Study Cohorts. Int J Gynecol Cancer. 2009;19(5):934-42. PubMed PMID: 19574788.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts. AU - Syrjänen,Kari, AU - Shabalova,Irena, AU - Naud,Paulo, AU - Kozachenko,Vladimir, AU - Derchain,Sophie, AU - Zakharchenko,Sergej, AU - Roteli-Martins,Cecilia, AU - Nerovjna,Raisa, AU - Longatto-Filho,Adhemar, AU - Kljukina,Ludmila, AU - Tatti,Silvio, AU - Branovskaja,Marina, AU - Hammes,Luciano Serpa, AU - Branca,Margherita, AU - Grunjberga,Valerija, AU - Erzen,Mojca, AU - Sarian,Luis Otavio, AU - Juschenko,Anna, AU - Costa,Silvano, AU - Podistov,Jurij, AU - Syrjänen,Stina, AU - ,, PY - 2009/7/4/entrez PY - 2009/7/4/pubmed PY - 2009/9/2/medline SP - 934 EP - 42 JF - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society JO - Int. J. Gynecol. Cancer VL - 19 IS - 5 N2 - BACKGROUND: New end points are needed in future human papillomavirus (HPV) vaccine efficacy studies that accurately predict disease progression. OBJECTIVES: Potential intermediate end points were analyzed in the combined New Independent States of the Former Soviet Union (NIS) and the Latin American Screening (LAMS) study cohorts. STUDY DESIGN AND METHODS: Data files of 2 international screening trials, the NIS (n = 3187) and the LAMS (n = 12,114) study cohorts, were combined, and a subcohort of 1865 (n = 854 and n = 1011 for the NIS and the LAMS, respectively) women prospectively followed up for 19.7 (median, 22.2) months was analyzed for different intermediate end-point markers of disease progression to squamous intraepithelial lesion (SIL), cervical intraepithelial neoplasia grade 1 and higher (CIN1+), and CIN grade 2 and higher (CIN2+) as terminal events. RESULTS: : Altogether, 131 (7.0%), 90 (4.8%), and 39 (2.1%) cases progressed to SIL, CIN1+, and CIN2+, respectively, progression times being equal in the NIS (11.9, 16.8, and 19.6 months) and LAMS (13.6, 14.1, and 15.4 months) cohorts (P = 0.931, P = 0.335, and P = 0.535). The 2 most powerful end-point markers of disease progression to CIN2+ were high-grade squamous intraepithelial lesions based on Papanicolaou test results at 6-month (odds ratio [OR] = 47.1; 95% confidence interval [CI], 17.3-128.7) and 12-month (OR = 21.5; 95% CI, 5.1-90.8) follow-up visits, with longitudinal positive and negative predictive values of 42.1% and 98.0% (6 months) and 33.3% and 97.7% (12 months). Of the virological end points, more than 6 months of persistent high-risk HPV (HR-HPV) was the most powerful predictor of progression to CIN1+ (OR = 18.6; 95% CI, 2.5-136.5), with longitudinal positive and negative predictive values of 10.3% and 99.4%, respectively. No additional benefit was obtained using more than 12 months of persistent HR-HPV end point. CONCLUSIONS: High-grade squamous intraepithelial lesion based on a Papanicolaou test results at 6- or 12-month follow-up visits was the most powerful end point, either considering cytological end points alone or in comparison to any of the virological end points. Of the virological end points, more than 6-month HR-HPV persistence criteria give the most powerful estimate of a progressive disease. SN - 1525-1438 UR - https://www.unboundmedicine.com/medline/citation/19574788/Persistent_high_risk_human_papillomavirus_infections_and_other_end_point_markers_of_progressive_cervical_disease_among_women_prospectively_followed_up_in_the_New_Independent_States_of_the_Former_Soviet_Union_and_the_Latin_American_Screening_study_cohorts_ L2 - http://ijgc.bmj.com/cgi/pmidlookup?view=long&pmid=19574788 DB - PRIME DP - Unbound Medicine ER -